The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 48.50
High: 49.00
Low: 48.50
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

15 Feb 2016 07:00

RNS Number : 9846O
Cambridge Cognition Holdings PLC
15 February 2016
 

15th February 2016

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Directorate Change

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets computerised neuropsychological tests including those enabling the early detection of dementia, announces the appointment of Steven Powell as Chief Executive Officer ('CEO'). This confirms the role he accepted in July 2015 when the then CEO, Nick Kerton, took an extended leave of absence from the Company due to a serious medical condition.

 

With over 25 years of operational and investment experience in the pharmaceutical and life sciences sector, Steven joined the Company as Head of European Operations in 2014. In this position, he was heavily involved in the development and implementation of the current product strategy, which is now starting to establish the Company as the leading provider of point of care cognitive assessments for dementia. Since his appointment to the board as COO and Interim CEO in July 2015, he has driven that strategy forward successfully. As a result, the transition from COO to CEO has been a natural one under the circumstances.

 

Nick Kerton will remain as a Non-Executive Director continuing to support the Company with his extensive technical and market knowledge.

 

Non-Executive Chairman at Cambridge Cognition, Michael Lewis commented: "We would like to thank Nick for his significant contribution to the development of Cambridge Cognition and we are delighted that Steven has accepted the permanent role of CEO to continue the excellent work that he has been doing since July last year. I am sure that he will continue to develop our management team, evolve the strategy and take the business on to the next level."

 

Steven Powell, CEO of Cambridge Cognition, commenting on his new role: "I am delighted that I have the confidence of the board to lead the Company to the next phase of growth by implementing the plans that we have been formulating over the past year."  

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Steven Powell, Chief Operating Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Lianne Cawthorne

Mob: 07584 391 303

Paul McManus

Mob: 07980 541 893

 

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAMMGMZVZFGVZM
Date   Source Headline
8th Apr 20214:40 pmRNSSecond Price Monitoring Extn
8th Apr 20214:36 pmRNSPrice Monitoring Extension
8th Apr 20212:06 pmRNSSecond Price Monitoring Extn
8th Apr 20212:00 pmRNSPrice Monitoring Extension
8th Apr 202111:05 amRNSSecond Price Monitoring Extn
8th Apr 202111:00 amRNSPrice Monitoring Extension
8th Apr 20217:00 amRNSNew £0.5m contract for cognitive at home testing
30th Mar 20217:00 amRNS£1.3 million contract for a schizophrenia trial
23rd Mar 20217:00 amRNSResults for the year ended 31 December 2020
11th Mar 20217:00 amRNSInvestor Presentation
17th Feb 20216:20 pmRNSHolding(s) in Company
19th Jan 20216:03 pmRNSHolding(s) in Company
19th Jan 202111:06 amRNSSecond Price Monitoring Extn
19th Jan 202111:00 amRNSPrice Monitoring Extension
19th Jan 20217:00 amRNSTrading Update, Board Change & Notice of Results
21st Dec 20207:00 amRNSNew digital health contract worth over £700,000
2nd Dec 20201:10 pmRNSHolding(s) in Company
2nd Nov 20202:55 pmRNSGrant of Options
7th Oct 20207:00 amRNSNew £750,000 digital health contract
5th Oct 20207:00 amRNSInvestor Presentation
22nd Sep 20207:00 amRNSInterim Results
21st Sep 20203:13 pmRNSHolding(s) in Company
14th Sep 20207:00 amRNSAppointment of Non-Executive Director
8th Sep 20209:57 amRNSNotice of Results
7th Sep 202012:19 pmRNSHolding(s) in Company
1st Sep 20207:00 amRNS£2m contract for three schizophrenia trials
27th Jul 20201:11 pmRNSResult of AGM and Board Changes
15th Jul 20207:00 amRNSNew virtual study with COVID-19 healthcare workers
3rd Jul 20203:30 pmRNSPosting of Annual Report & Notice of AGM
30th Jun 20209:00 amRNSAnnual Report & Notice of AGM
30th Jun 20207:00 amRNSTrading Update
23rd Jun 20204:18 pmRNSHolding(s) in Company
9th Jun 20207:00 amRNSGrant of Options
5th Jun 20207:00 amRNSCapital Markets Showcase
27th May 20207:00 amRNSOver £1 million of New Contract Wins
6th May 20206:11 pmRNSHolding(s) in Company
6th May 202012:15 pmRNSHolding(s) in Company
5th May 20207:00 amRNSPreliminary Results - Year ended 31 December 2019
29th Apr 20202:19 pmRNSNotice of Results
14th Apr 20207:00 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSHolding(s) in Company
23rd Mar 20204:00 pmRNSDelayed Preliminary Results
19th Mar 20207:00 amRNSAward of Innovative Medicines Initiative grant
17th Mar 20207:00 amRNS£1.37 million of new eCOA contracts
10th Mar 20204:15 pmRNSHolding(s) in Company
10th Mar 20204:15 pmRNSHolding(s) in Company
9th Mar 202012:46 pmRNSResult of General Meeting
19th Feb 20207:01 amRNSFundraising to raise £1.4m & Notice of GM
19th Feb 20207:00 amRNSTrading Update and Notice of Results
10th Jan 20203:54 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.